People: Aegerion Pharmaceuticals Inc (AEGR.O)
19 Sep 2014
Mr. Sandford D. Smith serves as an Independent Director of Aegerion Pharmaceuticals Inc., since January 2012. Mr. Smith is currently a Managing Director of Tullis Health Investors, which manages a family of funds and investments focusing on the healthcare industry. Prior to joining Tullis Health Investors in January 2012, Mr. Smith served from 1996 until 2011 in various senior and executive management positions at Genzyme Corporation, including most recently as Executive Vice President and President, International Group with responsibility for the commercial activities for Genzyme’s products outside of the U.S. Prior to joining Genzyme, Mr. Smith served from 1986 to 1996 as President and Chief Executive Officer and a Director of Repligen Corporation. Mr. Smith previously held a number of positions with Bristol-Myers Squibb Company from 1977 to 1986, including Vice President of Business Development and Strategic Planning for the Pharmaceutical Group. Mr. Smith currently serves as a director of Cytokynetics, Inc. (a biopharmaceutical company) and BioBehavioral Diagnostics Company (a privately held company that manufactures and markets technologies for the diagnosis and management of neurological and psychiatric conditions), and serves as a member of the President’s Advisory Board of Brigham and Women’s Hospital in Boston. During the past five years, Mr. Smith has served as a director of Ariad Pharmaceuticals, Inc. and Nventa Biopharmaceuticals Corporation. Mr. Smith holds a B.S. degree from the University of Denver.
|Total Annual Compensation,||Long-Term Incentive Plans,||All Other,||Fiscal Year Total,|